Complex endometrial hyperplasia

Summary

Complex endometrial hyperplasia (MONDO:0006169) is a disease. A subtype of hyperplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	complex endometrial hyperplasia
Mondo ID	MONDO:0006169
EFO	EFO:1000202
NCIT	C35423
SNOMED CT	198322002
UMLS	C0349578
MedGen	83889
Is cancer (heuristic)	no

Disease family

This is a subtype of hyperplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › hyperplasia › complex endometrial hyperplasia

Related subtypes (13): adrenal medullary hyperplasia, atypical endometrial hyperplasia, atypical lobular breast hyperplasia, C-cell hyperplasia, columnar cell hyperplasia of the breast, endometrial hyperplasia without atypia, parathyroid hyperplasia, simple endometrial hyperplasia, usual ductal breast hyperplasia, focal epithelial hyperplasia, benign prostatic hyperplasia, neuroendocrine cell hyperplasia of infancy, urothelial hyperplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.